StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Relacorilant

HCID 73051463
Neue Reaktion
Drucken

Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen

GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
1496510-51-0
Standard-SMILES
Cn1cc(S(=O)(=O)N2CCC3=Cc4c(cnn4-c4ccc(F)cc4)C[C@]3(C(=O)c3cc(C(F)(F)F)ccn3)C2)cn1
InChIKey
WANIDIGFXJFFEL-SANMLTNESA-N
Summenformel
C27H22F4N6O3S
Durchschnittliche Molmasse
586,6 g/mol
Monoisotopische Masse
586,14102241

Überblick

Relacorilant is a first-in-class, selective glucocorticoid receptor antagonist. Originally investigated to manage the metabolic and endocrinologic complications of hypercortisolism, such as Cushing’s syndrome, its clinical utility has pivoted toward oncology as a potent sensitizing agent. By competitively blocking the glucocorticoid receptor, relacorilant prevents cortisol from activating anti-apoptotic survival pathways, thereby restoring the efficacy of cytotoxic therapies in the context of resistant cancers. Relacorilant was approved by the US FDA on March 25, 2026, for use in combination with [paclitaxel] in patients with certain platinum-resistant cancers.

Namen und Bezeichner

Bevorzugter Name
Relacorilant
IUPAC
[(4aR)-1-(4-fluorophenyl)-6-(1-methylpyrazol-4-yl)sulfonyl-4,5,7,8-tetrahydropyrazolo[5,4-g]isoquinolin-4a-yl]-[4-(trifluoromethyl)-2-pyridinyl]methanone
Englischer Name
(R)-(1-(4-fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-1,4,5,6,7,8-hexahydro-4aH-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone
Summenformel
C27H22F4N6O3S
Molmasse
586.56

Namen und Synonyme

Relacorilant1496510-51-0CORT125134CORT-1251342158753C7EDTXSID801099345Methanone, ((4aR)-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4ah-pyrazolo(3,4-g)isoquinolin-4a-yl)(4-(trifluoromethyl)-2-pyridinyl)-Methanone, [(4aR)-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-6-[(1-methyl-1H-pyrazol-4-yl)sulfonyl]-4aH-pyrazolo[3,4-g]isoquinolin-4a-yl][4-(trifluoromethyl)-2-pyridinyl]-[(4aR)-1-(4-Fluorophenyl)-1,4,5,6,7,8-hexahydro-6-[(1-methyl-1H-pyrazol-4-yl)sulfonyl]-4aH-pyrazolo[3,4-g]isoquinolin-4a-yl][4-(trifluoromethyl)-2-pyridinyl]methanone2-[(4aR)-1-(4-fluorophenyl)-6-[(1-methyl-1H-pyrazol-4-yl)sulfonyl]-1H,4H,4aH,5H,6H,7H,8H-pyrido[3,4-f]indazole-4a-carbonyl]-4-(trifluoromethyl)pyridine((4aR)-1-(4-fluorophenyl)-6-(1-methyl-1H-pyrazole-4-sulfonyl)-1,4,5,6,7,8-hexahydro-4aH-pyrazolo(3,4-g)isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanonerelacorilantum
Weitere Namen anzeigen

Eigenschaften

Berechnete StruktureigenschaftenWird ergänzt

XLogP
2,9
Polarare Oberfläche (TPSA)
111 Ų
H-Brücken-Donoren
0
H-Brücken-Akzeptoren
11
Frei drehbare Bindungen
5
Schwere Atome
41
Formalladung
0
Komplexität
1.140

Experimentelle und physikochemische Eigenschaften

SolubilityPractically insoluble
Human Drugs · 2 Einträge

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Physikochemische Eigenschaften

Siedepunkt
715.8 · 715.8±70.0 °C(Predicted)
Dichte
1.54 · 1.54±0.1 g/cm3(Predicted)
pka
0.24 · 0.24±0.40(Predicted)
Aggregatzustand
Solid
Farbe
White to off-white
InChIKey
WANIDIGFXJFFEL-SANMLTNESA-N
SMILES
C([C@@]12C(=CC3N(C4=CC=C(F)C=C4)N=CC=3C1)CCN(S(C1=CN(C)N=C1)(=O)=O)C2)(C1=NC=CC(C(F)(F)F)=C1)=O

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

Sicherheitsdaten

Alarmwort
Warnung
Gefahrenhinweise
Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code H302

Chemie und Industrie

Pharmakologische Informationen

Protein BindingProtein binding of relacorilant in human plasma is >99% _in vitro_.
Pharmacodynamics · 1 Eintrag

In a healthy-volunteer study, relacorilant 500 mg (single dose) and 250 mg daily for 14 days was demonstrated to reverse all the effects of prednisone 25 mg. In a phase 1 study, RNA profiling after 15 days of treatment with relacorilant and nab-paclitaxel showed on-target suppression of GR-dependent genes - including PTGS2, CXCL8, PTGER4, and IDO1 - that correlated with response to relacorilant and nab-paclitaxel therapy. Relacorilant antagonizes the effects of co-administered glucocorticoids, and is therefore contraindicated in patients that require exogenous glucocorticoids for a life-threatening condition.

Mechanism of Action · 1 Eintrag

Relacorilant is a potent and selective modulator of the glucocorticoid receptor (GR), with an inhibition constant (Ki) for receptor binding of 0.15 nM, and no measurable binding to other steroid receptors. In ovarian carcinoma cell lines, GR activation leads to upregulation of glucocorticoid-regulated kinase 1 (SGK1) and map kinase phosphatase 1 (MKP1)/dual-specificity phosphatase 1 (DUSP1) genes. In this context, cortisol binding to the GR is immunosuppressive, decreasing the secretion of pro-inflammatory cytokines. The antagonism of GR by relacorilant may therefore indirectly activate the immune system, thereby enhancing the apoptosis and anti-tumor activity of co-administered paclitaxel.

Biological Half-LifeRelacorilant's terminal half-life in humans is 27 hours. In mice, the plasma half-life was 0.69 hours following intravenous dosing and 1.62 hours following oral dosing.
Metabolism/Metabolites · 1 Eintrag

Relacorilant is primarily metabolized by cytosolic reductases and CYP3A. An active metabolite, CORT125295, has functional activity approximately 5-fold lower than relacorilant and represents 75% of the parent AUC. Relacorilant is a strong CYP3A inhibitor and a weak CYP2C8 inducer, and both relacorilant and CORT125295 are inducers of CYP1A2 _in vitro_.

Zugehörige Reaktionen

2
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 537283
HRID 537283als Produkt
Reaktionsgleichung von HRID 920655
HRID 920655als Produkt

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
(R)-(1-(4-Fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone
EOS-61931
Relacorilant (CORT125134)
Relacorilant, 10 mM in DMSO
CORT125134 (RELACORILANT) ( CORT-125134)
(R)-(1-(4-fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-1,4,5,6,7,8-hexahydro-4aH-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone
((4aR)-1-(4-Fluorophenyl)-1,4,5,6,7,8-hexahydro-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4aH-pyrazolo(3,4-g)isoquinolin-4a-yl)(4-(trifluoromethyl)-2-pyridinyl)methanone[(4aR)-1-(4-Fluorophenyl)-6-(1-methyl-1H-pyrazole-4-sulfonyl)-1,4,5,6,7,8-hexahydro-4aH-pyrazolo[3,4-g]isoquinolin-4a-yl][4-(trifluoromethyl)pyridin-2-yl]methanone2-((4aR)-1-(4-fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-1H,4H,4aH,5H,6H,7H,8H-pyrido(3,4-f)indazole-4a-carbonyl)-4-(trifluoromethyl)pyridineRefChem:930638DTXCID901531081Lifyorli[(4aR)-1-(4-fluorophenyl)-6-(1-methylpyrazol-4-yl)sulfonyl-4,5,7,8-tetrahydropyrazolo[3,4-g]isoquinolin-4a-yl]-[4-(trifluoromethyl)pyridin-2-yl]methanoneRelacorilant [INN]

Datenbank-Bezeichner

CAS
1496510-51-0
PubChem CID
73051463
DTXSID
DTXSID801099345
ChEMBL
CHEMBL4068611
UNII
2158753C7E
Nikkaji
J3.651.009I
MeSH Pharmacological Classification
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Absorption, Distribution and Excretion · 4 Einträge

Following the third consecutive daily dose, relacorilant Cmax and AUC is 720 ng/mL and 5,686 ng*h/mL, respectively. The median Tmax is 2.5 hours. When co-administered with a low-fat meal, relacorilant Cmax increased 1.7-fold, AUC increased 2-fold, and Tmax was delayed by 0.5 hours. When co-administered with a high-fat meal, relacorilant Cmax was increased 1.9-fold, AUC increased 2.4-fold, and Tmax was delayed by 0.25 hours. In mice, the bioavailability of relacorilant was estimated at 20.5% after oral dosing.

After a single oral dose of radiolabeled relacorilant 250 mg to healthy participants, about 73% of the dose was recovered in feces (<1% as unchanged parent drug) and 17% was recovered in urine (<2% unchanged).

Relacorilant's apparent volume of distribution is 2490 L after a single 150 mg dose under fasted conditions.

Relacorilant's apparent total clearance is 52 L/h under fasted conditions.